HSIC vs INVA: fair value comparison
Henry Schein, Inc. and Innoviva, Inc. · Updated 2026-10-19
HSIC currently screens as fairly valued while INVA screens as undervalued. Within Healthcare, INVA currently sits closer to the top of our ranking by discount to fair value. INVA carries the stronger quality grade.
| HSIC | INVA | |
|---|---|---|
| Verdict | Fairly valued | Undervalued |
| Last price | $84.01 | $20.78 |
| 12-month range | $62.32–$90.86 | $17.57–$24.24 |
| Rank by discount to fair value | #47 of 108 Healthcare | #43 of 108 Healthcare |
| Quality grade | F | A |
| Leverage | Moderate | Low |
| Margin trend | Stable | Contracting |
| Revenue growth | Modest | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Downtrend |
| DCF cross-check | Overvalued | Undervalued |
| 52-week position | The top quarter | The lower-middle quarter |
Full single-stock breakdowns: HSIC fair value analysis · INVA fair value analysis